We are excited to announce that SilicoGene has joined the NVIDIA Inception Program. This program gives us access to advanced AI tools and resources, enabling us to enhance our MLOps services. With NVIDIA’s support, we will help our users efficiently develop and deploy AI models in the health-tech space, improving the way they approach drug discovery and personalized medicine.
About the NVIDIA Inception Program
The NVIDIA Inception Program is designed to support startups with access to AI and deep learning technologies. For SilicoGene, this means we can further improve our MLOps MLOps for Health-Tech services, offering our users the tools they need to build and manage their own AI models for healthcare and biotechnology.
How SilicoGene Benefits from NVIDIA Inception
With NVIDIA’s SDKs, credits, and discounts, we can reduce our infrastructure costs while enhancing the services we offer. This allows us to focus on helping our users develop, train, and deploy their own AI models within our platform. By leveraging NVIDIA’s technology, our users will have the power to accelerate their AI-driven healthcare innovations.
“We’ve completed the development of our RNA-seq data analysis services, which allows users to analyze omics data and use the results as input for their AI models. This analysis process is part of our MLOps services, specifically the ETL process. Instead of developing full omics analysis pipelines like WES and WGS, we’ve decided to focus on AI model life cycles. Training and deploying deep learning models require accelerated computing, which is why NVIDIA’s resources are crucial,” said Hossein Kamar, founder of SilicoGene.
Focus on MLOps for Health-Tech
At SilicoGene, we provide MLOps services that help users efficiently manage their AI model development process. Our platform focuses on ensuring that users can build and deploy reliable AI models for drug discovery and personalized medicine. With NVIDIA’s support, we can enhance these capabilities, enabling our users to bring their innovations to life.
